|
lipidomics |
25 |
|
humans |
18 |
|
enterovirus |
16 |
|
fatty acid |
16 |
|
uplc-esi-q-tof-ms |
16 |
|
virulence |
13 |
|
microbial sensitivity tests |
12 |
|
sequence analysis, dna |
12 |
|
antimicrobial |
11 |
|
antiviral agents - chemical synthesis - chemistry - pharmacology |
11 |
|
carboxypeptidases - antagonists & inhibitors - metabolism |
11 |
|
hemagglutinin |
11 |
|
mrsa |
11 |
|
sars virus - drug effects - growth & development - metabolism - physiology |
11 |
|
severe acute respiratory syndrome - drug therapy |
11 |
|
viral matrix proteins - antagonists & inhibitors - metabolism |
11 |
|
anti-bacterial agents - pharmacology |
10 |
|
antiviral |
10 |
|
base sequence |
10 |
|
cell line |
10 |
|
interferon |
10 |
|
s. aureus |
10 |
|
adenosine synthase a |
9 |
|
cell surface |
9 |
|
covid-19 |
9 |
|
entry |
9 |
|
influenza |
9 |
|
influenza virus |
9 |
|
internalization |
9 |
|
nucleolin |
9 |
|
phosphatidic acid phosphatases |
9 |
|
sars-cov-2 |
9 |
|
severe acute respiratory syndrome |
9 |
|
vopba |
9 |
|
biology |
8 |
|
biotechnology technology: comprehensive works medical sciences chemistry |
8 |
|
coronavirus |
8 |
|
molecular sequence data |
8 |
|
adult |
7 |
|
anti-influenza |
7 |
|
antibodies, viral - blood |
7 |
|
antiviral agents - pharmacology |
7 |
|
antiviral compounds |
7 |
|
aspergillus fumigatus |
7 |
|
biofilms - drug effects |
7 |
|
bromocriptine |
7 |
|
chlorogenic acid - chemistry - pharmacology |
7 |
|
cross-protection |
7 |
|
drug synergism |
7 |
|
epidemics |
7 |
|
female |
7 |
|
flavonoids - chemistry - pharmacology |
7 |
|
fungus protein |
7 |
|
gene |
7 |
|
glycyrrhizic acid - chemistry - pharmacology |
7 |
|
hcov-229e |
7 |
|
interferon-alpha - pharmacology |
7 |
|
interferon-beta - pharmacology |
7 |
|
lopinavir |
7 |
|
male |
7 |
|
membrane glycoproteins - genetics - immunology |
7 |
|
mers-cov |
7 |
|
middle aged |
7 |
|
ms |
7 |
|
nlrp3 inflammasome |
7 |
|
nucleocapsid proteins - genetics - immunology |
7 |
|
nucleoprotein |
7 |
|
polymerase assembly |
7 |
|
protease |
7 |
|
pyrimidinones - pharmacology |
7 |
|
ribavirin - pharmacology |
7 |
|
rimantadine - pharmacology |
7 |
|
sars virus - drug effects |
7 |
|
severe acute respiratory syndrome - diagnosis - virology |
7 |
|
severe acute respiratory syndrome - virology |
7 |
|
small-molecule inhibitor |
7 |
|
staphylococcus aureus |
7 |
|
surface modification |
7 |
|
t cell responses |
7 |
|
transcription, genetic |
7 |
|
treatment |
7 |
|
uhplc |
7 |
|
viral envelope proteins - genetics - immunology |
7 |
|
viral plaque assay |
7 |
|
virulence factors |
7 |
|
zika |
7 |
|
arachidonic acid |
6 |
|
binding sites |
6 |
|
bioluminescent bacteria |
6 |
|
broad-spectrum |
6 |
|
co-evolution |
6 |
|
co-immunoprecipitation |
6 |
|
cross infection - complications |
6 |
|
crystal structure |
6 |
|
d222g |
6 |
|
disease outbreaks |
6 |
|
drugs, chinese herbal - chemistry - pharmacology |
6 |
|
evolution, molecular |
6 |
|
fructus mume |
6 |
|
gene expression regulation, fungal |
6 |
|
genetic vectors |
6 |
|
genome, fungal |
6 |
|
guanosine |
6 |
|
heat-shock response - genetics |
6 |
|
hemagglutinin glycoproteins, influenza virus - chemistry - genetics |
6 |
|
hiv protease inhibitors - therapeutic use |
6 |
|
host-targeted antiviral |
6 |
|
influenza a |
6 |
|
influenza a virus, h1n1 subtype - genetics - immunology |
6 |
|
inhibitor |
6 |
|
innate immune evasion |
6 |
|
middle east |
6 |
|
mp1p-lbd2 |
6 |
|
mycophenolic acid |
6 |
|
nmr interaction titration |
6 |
|
orthodontic |
6 |
|
orthodontic brackets - microbiology |
6 |
|
pandemic |
6 |
|
penicillium - genetics |
6 |
|
penicillium - genetics - metabolism |
6 |
|
penicillium marneffei |
6 |
|
plant extracts - analysis - pharmacology |
6 |
|
polymerase inhibitor |
6 |
|
proinflammatory signaling lipid |
6 |
|
pyrimidinones - therapeutic use |
6 |
|
respiratory virus |
6 |
|
ribavirin |
6 |
|
ritonavir - therapeutic use |
6 |
|
saer |
6 |
|
self-antibacterial effect |
6 |
|
severe acute respiratory syndrome - drug therapy - virology |
6 |
|
structural evolution |
6 |
|
talaromyces marneffei |
6 |
|
target |
6 |
|
virulence mechanism |
6 |
|
zno nanowire |
6 |
|
adjuvants |
5 |
|
antibiotic tolerance |
5 |
|
antimicrobial agents/inhibitors |
5 |
|
antimicrobial effect |
5 |
|
antitubercular agents - pharmacology |
5 |
|
arachidonic acid (aa) |
5 |
|
bacteria |
5 |
|
bacterial proteins - genetics |
5 |
|
broad-spectrum antivirals |
5 |
|
chinese medicine |
5 |
|
drugs, chinese herbal - pharmacology |
5 |
|
escherichia coli - genetics - metabolism |
5 |
|
expression |
5 |
|
fungi |
5 |
|
gastroenteritis - microbiology |
5 |
|
gene expression regulation, bacterial |
5 |
|
genes, bacterial |
5 |
|
glutathione transferase - genetics - metabolism |
5 |
|
green fluorescent proteins - genetics - metabolism |
5 |
|
inducible |
5 |
|
isoniazid - pharmacology |
5 |
|
laribacter hongkongensis |
5 |
|
lipid-protein interaction |
5 |
|
microbiology |
5 |
|
mycobacterium tuberculosis - drug effects - genetics - isolation & purification |
5 |
|
neisseriaceae - genetics - isolation & purification - metabolism |
5 |
|
neisseriaceae infections - microbiology |
5 |
|
nuclear magnetic resonance |
5 |
|
oral biofilm |
5 |
|
persistent infections |
5 |
|
persister |
5 |
|
plant extracts - pharmacology |
5 |
|
plasmids |
5 |
|
porphyromonas gingivalis - drug effects |
5 |
|
prunus |
5 |
|
pyrimidine synthesis inhibitor |
5 |
|
respiratory tract infections |
5 |
|
shuttle vector |
5 |
|
titanium alloy |
5 |
|
transformation, genetic |
5 |
|
x-ray crystallography |
5 |
|
adsa |
4 |
|
anti-infective agents - pharmacology |
4 |
|
antibacterial |
4 |
|
antimicrobial property |
4 |
|
antivirulence |
4 |
|
autophagy |
4 |
|
bacteremia - microbiology |
4 |
|
bacterial infection |
4 |
|
biocompatibility |
4 |
|
cleavage of s protein |
4 |
|
cloning, molecular |
4 |
|
clostridium difficile |
4 |
|
clpp |
4 |
|
dna gyrase - chemistry - genetics |
4 |
|
dna vaccine |
4 |
|
dna, bacterial - chemistry - genetics |
4 |
|
drug resistance, bacterial - genetics |
4 |
|
epstein-barr virus (ebv) |
4 |
|
factor xa - metabolism |
4 |
|
fluoroquinolones - pharmacology |
4 |
|
hong kong |
4 |
|
hospitals |
4 |
|
immunotherapy |
4 |
|
infection |
4 |
|
kidney - virology |
4 |
|
kinetics |
4 |
|
lytic induction therapy |
4 |
|
lytic reactivation |
4 |
|
membrane glycoproteins - metabolism |
4 |
|
methicillin-resistant staphylococcus aureus |
4 |
|
methicillin-resistant staphylococcus aureus - drug effects - isolation & purification |
4 |
|
microbial sensitivity tests - methods |
4 |
|
molecular biology |
4 |
|
molecular diagnostic techniques - methods |
4 |
|
molecular epidemiology |
4 |
|
multilocus sequence typing |
4 |
|
multivalent vaccine |
4 |
|
mutation |
4 |
|
mycobacterium tuberculosis - drug effects - genetics |
4 |
|
mycobacterium tuberculosis - genetics |
4 |
|
nasopharyngeal carcinoma (npc) |
4 |
|
orthopedic implant |
4 |
|
orthopedic implants |
4 |
|
plasma immersion ion implantation |
4 |
|
polymerase chain reaction |
4 |
|
polymerase chain reaction - methods |
4 |
|
protease factor xa |
4 |
|
protease inhibitor |
4 |
|
protein binding |
4 |
|
proteomics |
4 |
|
sars-cov |
4 |
|
spectrometry, fluorescence - methods |
4 |
|
spike protein |
4 |
|
staphylococcal infections - microbiology |
4 |
|
therapeutics |
4 |
|
toxin a (tcda) |
4 |
|
toxin b (tcdb) |
4 |
|
tuberculosis - diagnosis - microbiology |
4 |
|
tuberculosis, multidrug-resistant - diagnosis - microbiology |
4 |
|
tuberculosis, pulmonary - diagnosis - microbiology |
4 |
|
vancomycin |
4 |
|
vancomycin - pharmacology |
4 |
|
vancomycin resistance |
4 |
|
viral envelope proteins - metabolism |
4 |
|
virus activation - physiology |
4 |
|
virus replication - physiology |
4 |
|
γδ t cell |
4 |
|
3c-like protease |
3 |
|
abdominal infection |
3 |
|
animal cell |
3 |
|
animal experiment |
3 |
|
animal model |
3 |
|
animal tissue |
3 |
|
animals |
3 |
|
anti-bacterial agents - administration and dosage - pharmacology |
3 |
|
anti-virulence |
3 |
|
beta-lactams |
3 |
|
bioactive material |
3 |
|
biocompatible materials |
3 |
|
bone cement |
3 |
|
bone cements |
3 |
|
chitosan |
3 |
|
chromatography, high pressure liquid |
3 |
|
cysteine endopeptidases |
3 |
|
dna primers |
3 |
|
durapatite |
3 |
|
endopeptidases - metabolism |
3 |
|
epstein–barr virus |
3 |
|
escherichia coli - enzymology - genetics |
3 |
|
fluorogenic substrate |
3 |
|
gastric carcinoma |
3 |
|
gene delivery |
3 |
|
gentamicins - administration and dosage - pharmacology |
3 |
|
iron chelation |
3 |
|
lytic cycle |
3 |
|
main protease |
3 |
|
mechanical properties |
3 |
|
molecular structure |
3 |
|
nanomedicine |
3 |
|
nasopharyngeal carcinoma |
3 |
|
octaarginine |
3 |
|
recombinant proteins - antagonists & inhibitors - metabolism |
3 |
|
sars virus - enzymology |
3 |
|
small molecule inhibitor |
3 |
|
strontium-containing hydroxyapatite |
3 |
|
viral proteins - antagonists & inhibitors - metabolism |
3 |
|
amino acid substitution |
2 |
|
anti-infective agents - chemistry - pharmacology |
2 |
|
biocompatible materials - chemistry - pharmacology |
2 |
|
biofilm |
2 |
|
biomaterials |
2 |
|
biosurfactant |
2 |
|
candida albicans |
2 |
|
ceramics - chemistry - pharmacology |
2 |
|
curcumin |
2 |
|
filamentation |
2 |
|
metals - chemistry - pharmacology |
2 |
|
models, molecular |
2 |
|
mutagenesis, site-directed |
2 |
|
plasma surface modification |
2 |
|
ribonucleases - chemistry - genetics |
2 |
|
self-decontamination |
2 |
|
staphyloxanthin |
2 |
|
structure-activity relationship |
2 |
|
titanium - chemistry |
2 |
|
tumor cells, cultured |
2 |
|
alanine - genetics |
1 |
|
allergens |
1 |
|
amino acid sequence |
1 |
|
amino acid substitution - genetics |
1 |
|
angiogenin |
1 |
|
angiotensins - chemistry |
1 |
|
antibiotics, antineoplastic - metabolism |
1 |
|
anticarcinogenic agents - pharmacology |
1 |
|
antigens, plant |
1 |
|
antiviral agents - chemistry - pharmacology |
1 |
|
aspartic acid - genetics |
1 |
|
aspergillus - chemistry - genetics - metabolism |
1 |
|
aspergillus - pathogenicity |
1 |
|
aspergillus fumigatus - genetics |
1 |
|
bacterial translation |
1 |
|
binding sites - genetics |
1 |
|
carrier proteins |
1 |
|
cell proliferation - drug effects |
1 |
|
cercopithecus aethiops |
1 |
|
chromatography, affinity |
1 |
|
cloning, molecular - methods |
1 |
|
computational biology - methods |
1 |
|
computer simulation |
1 |
|
consensus scoring |
1 |
|
cysteine endopeptidases - chemistry - isolation & purification |
1 |
|
cytotoxic protein |
1 |
|
cytotoxins - chemistry - genetics - metabolism |
1 |
|
databases, factual |
1 |
|
dna mutational analysis |
1 |
|
dna primers - genetics |
1 |
|
dna-directed rna polymerases - metabolism |
1 |
|
drug evaluation, preclinical |
1 |
|
drug evaluation, preclinical - methods |
1 |
|
electrophoresis, polyacrylamide gel - methods |
1 |
|
endoribonucleases - chemistry - genetics - metabolism - toxicity |
1 |
|
endoribonucleases - chemistry - isolation & purification - metabolism |
1 |
|
endoribonucleases - genetics - isolation & purification |
1 |
|
enrichment |
1 |
|
enzyme inhibitor |
1 |
|
enzyme inhibitors - analysis - chemistry - metabolism |
1 |
|
eosinophil-derived neurotoxin |
1 |
|
eosinophils - enzymology |
1 |
|
escherichia coli - genetics |
1 |
|
false positives |
1 |
|
fermentation |
1 |
|
fluorescence-based protease assay |
1 |
|
fungal proteins - chemistry - genetics |
1 |
|
fungal proteins - chemistry - genetics - metabolism |
1 |
|
fungal proteins - chemistry - genetics - metabolism - toxicity |
1 |
|
fungal proteins - genetics - isolation & purification - metabolism |
1 |
|
fungal proteins - genetics - metabolism - toxicity |
1 |
|
fungal proteins - metabolism |
1 |
|
fungal proteins - toxicity |
1 |
|
fungi - enzymology |
1 |
|
genes, fungal |
1 |
|
genetic variation |
1 |
|
high-throughput screening |
1 |
|
hydrogen bonding |
1 |
|
hydrolysis |
1 |
|
hydroxylamine |
1 |
|
internally quenched fluorogenic peptide substrate |
1 |
|
ligand docking |
1 |
|
ligands |
1 |
|
lipid bilayers - chemistry - metabolism |
1 |
|
liposomes - metabolism |
1 |
|
macromolecular substances |
1 |
|
mice |
1 |
|
mice, nude |
1 |
|
microbial rnase |
1 |
|
mitogillin |
1 |
|
msmeg 2624 |
1 |
|
mutagens |
1 |
|
mycobacterium smegmatis |
1 |
|
mycotoxins - chemistry - genetics |
1 |
|
mycotoxins - chemistry - genetics - metabolism |
1 |
|
mycotoxins - chemistry - genetics - metabolism - toxicity |
1 |
|
mycotoxins - genetics - metabolism - toxicity |
1 |
|
mycotoxins - toxicity |
1 |
|
naphthalenesulfonates - pharmacology |
1 |
|
neoplasms - blood - prevention & control |
1 |
|
neovascularization, pathologic - prevention & control |
1 |
|
pichia - genetics |
1 |
|
plasmids - genetics |
1 |
|
point mutation |
1 |
|
porifera - chemistry - classification |
1 |
|
promoter regions, genetic |
1 |
|
protease inhibitors - chemistry - classification - pharmacology |
1 |
|
protein binding - genetics |
1 |
|
protein conformation |
1 |
|
protein denaturation |
1 |
|
protein structure, secondary |
1 |
|
protein structure, tertiary |
1 |
|
protein synthesis inhibitors - chemistry - metabolism |
1 |
|
protein-bilayer interaction |
1 |
|
proteins - chemistry - genetics |
1 |
|
rabbits |
1 |
|
recombinant proteins - chemistry - genetics - metabolism |
1 |
|
recombinant proteins - chemistry - isolation & purification - metabolism |
1 |
|
recombinant proteins - genetics - isolation & purification |
1 |
|
recombinant proteins - isolation & purification - metabolism |
1 |
|
recombinant proteins - pharmacology |
1 |
|
reproducibility of results |
1 |
|
restrictocin |
1 |
|
reticulocytes - drug effects - metabolism |
1 |
|
ribonuclease |
1 |
|
ribonuclease t1 - chemistry |
1 |
|
ribonuclease, pancreatic - antagonists & inhibitors |
1 |
|
ribonuclease, pancreatic - antagonists & inhibitors - chemistry - metabolism |
1 |
|
ribonucleases |
1 |
|
ribonucleases - chemistry - genetics - metabolism |
1 |
|
ribonucleases - chemistry - genetics - metabolism - toxicity |
1 |
|
ribonucleases - genetics - metabolism |
1 |
|
ribosome-inactivating protein |
1 |
|
ribosomes - drug effects |
1 |
|
ribosomes - metabolism |
1 |
|
ribotoxin |
1 |
|
rimp |
1 |
|
rna, fungal - metabolism |
1 |
|
rna, ribosomal - metabolism |
1 |
|
rnase t1 |
1 |
|
rpsl |
1 |
|
saccharomyces cerevisiae - genetics |
1 |
|
sars virus - drug effects - enzymology |
1 |
|
sars-coronavirus 3cl protease |
1 |
|
sensitivity and specificity |
1 |
|
sequence deletion |
1 |
|
sequence homology, amino acid |
1 |
|
site-directed mutagenesis |
1 |
|
specificity |
1 |
|
spectrometry, fluorescence |
1 |
|
substrate specificity |
1 |
|
targeted toxin |
1 |
|
temperature |
1 |
|
templates, genetic |
1 |
|
time factors |
1 |
|
transplantation, heterologous |
1 |
|
tyrosine - genetics |
1 |
|
umbelliferones - chemistry - pharmacology |
1 |
|
vero cells |
1 |
|
viral protease |
1 |
|
viral protease inhibitor |
1 |
|
viral proteins |
1 |
|
viral proteins - antagonists & inhibitors - chemistry - isolation & purification |
1 |
|
virtual screening |
1 |
|
virus replication - drug effects - physiology |
1 |
|
α-sarcin |
1 |
|
α-sarcin/ricin loop |
1 |
